Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

PHASE4CompletedINTERVENTIONAL
Enrollment

433

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily

DRUG

metformin

The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily

DRUG

repaglinide

The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.

Trial Locations (17)

200001

Novo Nordisk Investigational Site, Shanghai

200025

Novo Nordisk Investigational Site, Shanghai

200040

Novo Nordisk Investigational Site, Shanghai

200072

Novo Nordisk Investigational Site, Shanghai

200092

Novo Nordisk Investigational Site, Shanghai

200120

Novo Nordisk Investigational Site, Shanghai

210009

Novo Nordisk Investigational Site, Nanjing

210012

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

214023

Novo Nordisk Investigational Site, Wuxi

215004

Novo Nordisk Investigational Site, Suzhou

226001

Novo Nordisk Investigational Site, Nantong

310003

Novo Nordisk Investigational Site, Hangzhou

310016

Novo Nordisk Investigational Site, Hangzhou

325000

Novo Nordisk Investigational Site, Wenzhou

330006

Novo Nordisk Investigational Site, Nanchang

350001

Novo Nordisk Investigational Site, Fuzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00819741 - Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs | Biotech Hunter | Biotech Hunter